Literature DB >> 33914051

Association Between Removal of a Warning Against Cephalosporin Use in Patients With Penicillin Allergy and Antibiotic Prescribing.

Eric Macy1, Thomas A McCormick2, John L Adams2,3, William W Crawford4, Myngoc T Nguyen5, Liem Hoang6, Victoria Eng7, Anna C Davis2,3, Elizabeth A McGlynn2,3,8.   

Abstract

Importance: Electronic health records (EHRs) often include default alerts that can influence physician selection of antibiotics, which in turn may be associated with a suboptimal choice of agents and increased antibiotic resistance. Objective: To examine whether removal of a default alert in the EHR to avoid cephalosporin use in patients with penicillin allergies is associated with changes in cephalosporin dispensing or administration in these patients. Design, Setting, and Participants: This retrospective cohort study of a natural experiment included data on patients who had received antibiotic treatment in the hospital or outpatient setting in 2 regions of a large, integrated health system in California from January 1, 2017, to December 31, 2018. Of 4 398 792 patients, 4 206 480 met the eligibility criteria: enrollment in the health system during antibiotic use, availability of complete demographic data, and use of antibiotics outside of the washout period. Interventions or Exposures: Oral or parenteral antibiotics dispensed or administered after removal of an EHR alert to avoid cephalosporin use in patients with a recorded penicillin allergy. Main Outcomes and Measures: Probability that an antibiotic course was a cephalosporin. A multinomial logistic regression model was used to examine the change in rates of cephalosporin use before and after an EHR penicillin allergy alert was removed in 1 of the study regions. Temporal changes in use rates were controlled for by comparing changes in cephalosporin use among patients with or without a penicillin allergy at the site that removed the warning and among patients at a comparison site that retained the warning. Regression models were used to examine adverse events.
Results: Of the 4 206 480 patients who met all inclusion criteria, 2 465 849 (58.6%) were women; the mean (SD) age was 40.5 (23.2) years. A total of 10 652 014 antibiotic courses were administered or dispensed, divided approximately evenly between the period before and after removal of the warning. Before removal of an alert in the electronic health record system to avoid prescribing of cephalosporins to patients with a penicillin allergy at 1 of the 2 sites, 58 228 courses of cephalosporins (accounting for 17.9% of all antibiotic use at the site) were used among patients with a penicillin allergy; after removal of the alert, administration or dispensing of cephalosporins increased by 47% compared with cephalosporin administration or dispensing among patients without a penicillin allergy at the same site and patients at the comparison site that retained the warning (ratio of ratios of odds ratios [RROR], 1.47; 95% CI, 1.38-1.56) . No significant differences in anaphylaxis (9 total cases), new allergies (RROR, 1.02; 95% CI, 0.93-1.12), or treatment failures (RROR, 1.02; 95% CI, 0.99-1.05) were found at the course level. No significant differences were found in all-cause mortality (ratio of ratios of rate ratios [RRRR], 1.03; 95% CI, 0.94-1.13), hospital days (RRRR, 1.04; 95% CI, 0.99-1.10), and new infections (Clostridioides difficile: RRRR, 1.02; 95% CI, 0.84-1.22; methicillin-resistant Staphylococcus aureus: RRRR, 0.87; 95% CI, 0.75-1.00; and vancomycin-resistant Enterococcus: RRRR, 0.82; 95% CI, 0.55-1.22) at the patient level. Conclusions and Relevance: In this cohort study, removal of a warning in the electronic health record to avoid cephalosporin use in patients with penicillin allergies was associated with increased administration and dispensing of cephalosporin. This simple and rapidly implementable system-level intervention may be useful for improvement in antibiotic stewardship.

Entities:  

Year:  2021        PMID: 33914051     DOI: 10.1001/jamanetworkopen.2021.8367

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


  7 in total

1.  Improving Antibiotic Stewardship for Inpatients with Reported Beta-Lactam Allergies and Limited Access to Penicillin Skin Testing.

Authors:  Rebecca E Berger; Harjot K Singh; Angela S Loo; Victoria Cooley; Snezana Nena Osorio; Jennifer I Lee; Matthew S Simon
Journal:  Jt Comm J Qual Patient Saf       Date:  2021-12-09

Review 2.  Penicillin Allergy and Perioperative Anaphylaxis.

Authors:  Allison Ramsey
Journal:  Front Allergy       Date:  2022-06-09

3.  Safety of cefazolin for perioperative prophylaxis in patients with penicillin allergy labels.

Authors:  Jocelyn J Cooper; Vidya L Atluri; Rupali Jain; Paul S Pottinger; David T Coleman
Journal:  Ann Allergy Asthma Immunol       Date:  2022-03-24       Impact factor: 6.248

Review 4.  The Use of Electronic Health Records to Study Drug-Induced Hypersensitivity Reactions from 2000 to 2021: A Systematic Review.

Authors:  Fatima Bassir; Sheril Varghese; Liqin Wang; Yen Po Chin; Li Zhou
Journal:  Immunol Allergy Clin North Am       Date:  2022-03-31       Impact factor: 3.152

5.  Antibiotic Use in Patients With β-Lactam Allergies and Pneumonia: Impact of an Antibiotic Side Chain-Based Cross-Reactivity Chart Combined With Enhanced Allergy Assessment.

Authors:  Curtis D Collins; Renee S Bookal; Anurag N Malani; Harvey L Leo; Tara Shankar; Caleb Scheidel; Nina West
Journal:  Open Forum Infect Dis       Date:  2021-11-17       Impact factor: 3.835

6.  Prevention of congenital syphilis using ceftriaxone in a woman with Stevens-Johnson syndrome reaction to penicillin: A case report.

Authors:  Meredith Coyle; Shawn Depcinski; Muthayipalayam Thirumoorthi
Journal:  Case Rep Womens Health       Date:  2022-08-20

7.  Negative impact of penicillin allergy labels on antibiotic use in hospitalized patients in Chinese Mainland.

Authors:  Zihan Jiang; Hongting Zhang; Hao Xiao; Xiong Xiao; Juan Meng
Journal:  World Allergy Organ J       Date:  2022-08-24       Impact factor: 5.516

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.